FDA: Seroquel sales aid is misleading

Share this article:
The FDA has asked AstraZeneca to halt distribution of a professional sales aid used to market its antipsychotic medication Seroquel.

In a warning letter sent to AstraZeneca, the FDA's Division of Drug Marketing, Advertising & Communications (DDMAC) wrote that the sales aid is misleading because it minimizes the risk of side effects associated with Seroquel.

“The promotional material raises significant public health and safety concerns through its minimization of the risks associated with Seroquel,” DDMAC wrote.

AstraZeneca spokesman Jim Minnick told MM&M the company was working closely with the FDA to resolve the matter.

“The purpose of the piece was to convey to healthcare professionals accurate and scientifically substantiated information about the risk of diabetes, accompanied by a copy of the FDA approved product information product labeling,” Minnick said.   

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.